Peer Review in Toxicologic Pathology

10th ESTP Congress 2012
Stresa, Italy
Current Situation for Pathology
Peer Review in Japan

September 14, 2012

Taki Harada, DVM, PhD
Peer Review Ad hoc Working Group
The Japanese Society of Toxicologic Pathology
### Outline of Presentation

1. Regulatory Agencies in Japan
2. Current Pathology Peer Review (PPR) in Japan
3. Current Definition of Pathology Raw Data
4. Current Reporting Procedures in Japan
5. JSTP Actions to PPR
6. New Draft Proposal for PPR by PMDA
7. JSTP Position on PPR
### 1. Regulatory Agencies in Japan

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Guidelines</th>
<th>Risk Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceuticals:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthetic</td>
<td>MHLW (2000)</td>
<td>PMDA</td>
</tr>
<tr>
<td>Herb</td>
<td>MHLW*</td>
<td>PMDA</td>
</tr>
<tr>
<td>Food additives:</td>
<td>MHLW (1996)</td>
<td>Food Safety Commission</td>
</tr>
<tr>
<td>Health foods:</td>
<td>MHLW*</td>
<td>MHLW subcommittee</td>
</tr>
<tr>
<td>Agrochemicals:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthetic</td>
<td>MAFF (2000)</td>
<td>Food Safety Commission</td>
</tr>
<tr>
<td>Microbial</td>
<td>MAFF (1997)</td>
<td>Food Safety Commission</td>
</tr>
<tr>
<td>Veterinary drugs</td>
<td>MAFF (1985)</td>
<td>Food Safety Commission</td>
</tr>
<tr>
<td>Industrial chemicals:</td>
<td>METI/MHLW/ME (2001)</td>
<td>Food Safety Commission</td>
</tr>
</tbody>
</table>

* : Not specified, determined on case-by-case basis  
MHLW = Ministry of Health, Labor and Welfare  
MAFF = Ministry of Agriculture, Forest and Fisheries  
METI = Ministry of Economy, Trade and Industry  
ME = Ministry of the Environment  
PMDA = Pharmaceuticals and Medical Devices Agency
## 2. Current Pathology Peer Review in Japan

- Pathology peer review (PPR) is recommended to be conducted but not required by any of regulatory agencies in Japan.

- Only Pharmaceutical and Medical Devices Agency (PMDA) proposed a guidance in 2006, “PPR by pathologists from sponsors should be conducted after data locking”.

- Consequently, sponsor PPR for pharmaceuticals has been being conducted after pathology data is fixed in accordance with the proposed guidance 2006 by PMDA.
Current PPR Procedures in Japan

Study Pathologist (SP) (reads slide)

- Findings
- Work sheet

Internal PPR

Data locking

- Findings
- Work sheet signed and dated by SP (Raw data)

Sponsor PPR

Revised version

- Findings

If any changes, Document the history

Study Director (SD)

Final Report
3. Current Definition of Pathology Raw Data in Japan

- Pathology raw data is defined as findings described in the work sheets signed and dated by Study Pathologist (SP) in Japan.

- SP submits incidence data (Tables) and individual findings (Appendices) to Study Director after the data is finalized. However, pathology report signed and dated by SP is customarily not issued.
4. Current Reporting Procedures in Japan

- All the data generated during the conduct of a toxicological study are submitted to the Study Director (SD). Only SD prepare the final report based on the results gathered from each section.

- Therefore, Study Pathologist (SP) is not required to prepare a pathology report. Only pathology data signed and dated by SP is required to be submitted to SD.
5. JSTP Actions to Pathology Peer Review

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>International panel discussion on regulatory perspective for pathology data was held at the 25th JSTP Annual Meeting in 2009. It was recognized that the timing of PPR and definition of raw data considerably differ among US, Europe and Japan.</td>
</tr>
<tr>
<td></td>
<td>After a draft OECD guidance on PPR was proposed, the JSTP Peer Review Ad hoc Working Group discussed about the content with all members of the JSTP and consequently decided to endorse the STP position.</td>
</tr>
<tr>
<td></td>
<td>In 2010, the JSTP and other relevant parties had a couple of face to face meetings with PMDA and recommended that PPR prior to data locking would be more suitable to improve the quality of pathology data.</td>
</tr>
</tbody>
</table>
# 6. New Draft Proposal for PPR by PMDA

- PPR is not mandatory to nonclinical studies of pharmaceutical products, but if PPR is carried out, then it is subject of GLP inspection.

- At the moment, PMDA considers that pathology raw data is the report or data signed and dated by the study pathologist.

- PPR before or after data locking would be acceptable either way, but PPR by pathologists outside from sponsors or academia may be required to ensure the transparency of review process and to be described in the protocol if the conduct is scheduled in advance.

- In that case, the name of the pathology peer reviewer and reviewed organs with disagreement should be described in the final report.

- The report or data generated by the peer reviewer should be archived together with other study documents.
7. JSTP Position on Pathology Peer Review

- The JSTP basically agrees with the new draft proposal by PMDA, although we need further discussions in details before it is finalized.

- In principle, the JSTP position is consistent with that of STP which is shown in “Recommendations for Pathology Peer Review” published in *Toxicologic Pathology* in 2010.
Dream forever

Taki

Dream forever